Drug Search Results
More Filters [+]

Fasitibant

Alternative Names: fasitibant, men-16132, men16132, men 16132, fastibant
Latest Update: 2015-11-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: B2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fasitibant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Osteoarthritis, Knee|Arthritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALBATROSS-4

P2

Temporarily not available

Osteoarthritis, Knee

2015-08-21

ALBATROSS-3

P2

Completed

Osteoarthritis, Knee

2015-01-06

ALBATROSS-3

P2

Completed

Osteoarthritis, Knee

2015-01-01

ALBATROSS-2

P2

Completed

Arthritis

2013-02-01

Recent News Events

Date

Type

Title